Exact Sciences Intrinsic Value Calculation – Exact Sciences Receives Strong Buy Rating from Canaccord Genuity Group in Latest Research Report
September 17, 2024
☀️Trending News
In the latest research report released by Canaccord Genuity Group, Exact Sciences ($NASDAQ:EXAS) has received a strong buy rating for its shares. This reaffirms the company’s position in the market and highlights the potential for growth in the future. Exact Sciences is a leading company in the field of cancer diagnostics and precision medicine. The company aims to revolutionize cancer prevention and treatment through innovative technologies and diagnostic tools. With a strong focus on research and development, Exact Sciences has made significant strides in the medical industry, making it a lucrative investment option for investors. Having already established itself as a leader in the field of cancer diagnostics, the company’s shares have caught the attention of investors and analysts alike. Canaccord Genuity Group’s buy recommendation serves as a testament to the company’s strong financials, innovative products, and growth potential.
This is a reflection of the company’s strong financials and promising future prospects. Moreover, Exact Sciences has also made strategic acquisitions and partnerships that have further strengthened its position in the market. These include the acquisition of Genomic Health and a partnership with Pfizer, which have expanded the company’s portfolio and opened up new avenues for growth. The company has reported strong revenue growth in recent years, with its flagship product, Cologuard, driving a significant portion of its sales. With a growing demand for non-invasive cancer screening methods, Exact Sciences is well-positioned to capitalize on this market trend and continue its growth trajectory. With its innovative products, strategic partnerships, and impressive financials, Exact Sciences is well-poised to continue its upward trajectory and provide significant returns for investors.
Stock Price
On Monday, the stock of EXACT SCIENCES, a leading biotechnology company, opened at $66.69 and closed at $69.48. This was a significant increase of 6.01% from the previous closing price of $65.54. The strong buy rating is based on the latest research report by the investment bank, which highlights the company’s potential for growth and profitability in the coming years. Investors are particularly optimistic about EXACT SCIENCES’ innovative technology in cancer screening and diagnostics, which has shown promising results in detecting early-stage cancers. This potential breakthrough in cancer detection has caught the attention of healthcare professionals and investors alike, leading to a surge in the company’s stock price.
Furthermore, Canaccord Genuity Group’s research report also praises EXACT SCIENCES’ strong financial performance, with a steady increase in revenue and earnings over the past few years. This further reinforces the investment bank’s belief in the company’s potential for future growth. With this positive sentiment in the market, it is no surprise that the stock price has risen significantly since the release of the research report. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Exact Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 2.5k | -204.15 | -9.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Exact Sciences. More…
| Operations | Investing | Financing |
| 156.12 | 49.68 | 159.77 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Exact Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.47k | 3.33k | 17.34 |
Key Ratios Snapshot
Some of the financial key ratios for Exact Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 18.8% | – | -7.1% |
| FCF Margin | ROE | ROA |
| 1.3% | -3.5% | -1.7% |
Analysis – Exact Sciences Intrinsic Value Calculation
As a financial analyst, I have conducted a thorough analysis of EXACT SCIENCES and its financials. Based on my evaluation, I have determined that the fair value of EXACT SCIENCES share is approximately $88.9. This was calculated using our proprietary Valuation Line, which takes into account various financial metrics such as earnings, revenue, and growth potential. Currently, the stock is being traded at $69.48, which indicates that it is undervalued by 21.9%. This presents a potential opportunity for investors to purchase EXACT SCIENCES shares at a discounted price. The undervaluation is likely due to market sentiments or other external factors, rather than any fundamental issues with the company itself. In my analysis, I considered the company’s financial performance and future prospects. EXACT SCIENCES has shown strong growth in earnings and revenue over the past few years, and its innovative products in the field of cancer detection and screening have positioned it for continued growth in the future. Additionally, EXACT SCIENCES has a strong balance sheet with minimal debt and a healthy cash flow, which provides a stable foundation for the company’s operations and potential for expansion. Based on all of these factors, I am confident in my evaluation of EXACT SCIENCES and believe that it is currently undervalued in the market. As always, investors should conduct their own research and due diligence before making any investment decisions. More…
Peers
The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.
– Inoviq Ltd ($ASX:IIQ)
Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.
Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.
– Myriad Genetics Inc ($NASDAQ:MYGN)
Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.
Summary
Canaccord Genuity Group, a financial services company, maintained their buy rating on shares of Exact Sciences, a biotechnology company, in a recent research report. The stock price of Exact Sciences also saw an increase on the same day. This suggests that Canaccord Genuity Group remains confident in the company’s potential for growth and profitability. Investors may view this as a positive sign and consider taking a position in Exact Sciences based on the recommendation from Canaccord Genuity Group.
However, it is important for investors to conduct their own thorough analysis of the company before making any investment decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
